MedPath

JHP Pharmaceuticals LLC

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

1

FDA:1

Drug Approvals

sumatriptan succinate

Approval Date
Sep 4, 2009
FDA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (100.0%)

Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)

Phase 2
Conditions
Tuberculosis Identification.
First Posted Date
2013-02-25
Last Posted Date
2013-02-25
Lead Sponsor
JHP Pharmaceuticals LLC
Target Recruit Count
90
Registration Number
NCT01798121

Equivalence Study of Specificity of PPD

Phase 2
Conditions
Tuberculosis Infection
First Posted Date
2013-02-25
Last Posted Date
2013-02-25
Lead Sponsor
JHP Pharmaceuticals LLC
Target Recruit Count
152
Registration Number
NCT01798095
Locations
🇺🇸

The University of Texas Health Science Center at Tyler, Tyler, Texas, United States

Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)

Phase 2
Conditions
Tuberculosis Infection
First Posted Date
2012-09-21
Last Posted Date
2012-09-21
Lead Sponsor
JHP Pharmaceuticals LLC
Target Recruit Count
168
Registration Number
NCT01689831
Locations
🇺🇸

The University of Texas Health Science Center at Tyler, Tyler, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.